argenx’s Vyvgart Receives Approval from Health Canada to Treat Generalized Myasthenia Gravis (gMG)
Shots:
- The approval was granted based on the results from the P-III (ADAPT) clinical trial evaluating the safety & efficacy of Vyvgart vs PBO in patients (n=167) with gMG across North America, Europe & Japan. The 1EPs of the study included the comparison between the percentage of MG-ADL responders in 1st treatment cycle between Vyvgart vs PBO
- The results from the study depicted a more prevalent response from anti-AChR antibody-positive gMG patients on the MG-ADL (68% vs 30%) & QMG (63% vs 14%) scale after being treated with Vyvgart vs PBO
- Vyvgart is a human IgG1 antibody fragment that binds to the FcRn leading to the reduction of circulation IgG autoantibodies
Ref: Globenewswire | Image: argenx
Related News:- argenx's Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Receives the US FDA’s Approval for Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
